Amyl Therapeutics, a preclinical stage biotechnology company developing an innovative technology platform to treat diseases linked to

Amyl Therapeutics 是一家处于临床前阶段的生物技术公司，致力于开发一个创新的技术平台，以治疗与

amyloid fibrils

淀粉样纤维

, announces the successful completion of an €8.25M ($9.4M) extension of its

，宣布其825万欧元（940万美元）的扩展项目圆满完成

Series A financing

A轮融资

, with half of the funding provided through public grants and half by new private investors, including family offices and business angels, who have chosen to remain undisclosed, and existing shareholders, including Noshaq and Merieux Equity Partners.

其中一半资金通过公共拨款提供，另一半由新的私人投资者（包括选择保持匿名的家族办公室和天使投资人）以及现有股东（包括 Noshaq 和 Merieux Equity Partners）提供。

Pierre Vandepapelière, co-founder, CEO and CMO of Amyl Therapeutics

皮埃尔·范德帕佩利耶尔，Amyl Therapeutics 联合创始人、首席执行官兼首席营销官

Amyl Therapeutics

Amyl Therapeutics

In a market where financing for early-stage European biotechnology companies remains highly selective, this latest investment reflects the continued confidence in Amyl Tx’s differentiated approach and the strength of its scientific results.

在欧洲早期生物技术公司融资仍然高度选择性的市场环境下，这笔最新投资反映了投资者对Amyl Tx差异化方法及其科研成果实力的持续信心。

The proceeds will enable the company to finalize development of its fully characterized clinical candidate ready for GMP manufacturing, while generating the remaining preclinical

所得款项将使公司能够完成其全面表征的临床候选药物的开发，使其具备进行药品生产质量管理规范（GMP）生产的条件，同时开展剩余的临床前研究。

in vivo

体内

efficacy and safety data required to validate its platform.

验证其平台所需的疗效和安全性数据。

Better biosensor technology created for stem cells

为干细胞开发的更优生物传感器技术

Technology may help guide treatment of Alzheimer's, Parkinson's diseases

科技或有助于指导阿尔茨海默病和帕金森病的治疗

Read news

阅读新闻

This investment also marks an important step in Amyl Tx’s organizational growth. One of the company’s new lead family office investors will join the board of directors. To accommodate its expanding research activities, Amyl is extending its laboratory facilities at the LegiaPark life sciences campus in Liège and will double the size of its R&D team..

此次投资也标志着Amyl Tx在组织成长方面迈出了重要一步。公司的一位新的主要家族办公室投资者将加入董事会。为适应不断扩大的研究活动，Amyl正在扩展其位于列日LegiaPark生命科学园区的实验室设施，并计划将其研发团队规模扩大一倍。

'This financing is an important endorsement of both our science and our vision. We are deeply grateful for the continued confidence shown by our investors and public partners, whose support enables us to reach the next critical stage of our development,’ said Pierre Vandepapelière, co-founder, CEO and CMO of Amyl Therapeutics.

“此次融资是对我们的科学实力与愿景的重要认可。我们深切感谢投资者和公共合作伙伴持续展现的信任，他们的支持使我们能够迈入发展的下一个关键阶段。”Amyl Therapeutics 联合创始人、首席执行官兼首席医学官 Pierre Vandepapelière 表示。

“Our results already demonstrate that our fusion protein combines the therapeutic strengths of three monoclonal antibodies while addressing many key limitations in brain delivery and safety. Ultimately, our aim is to deliver a genuine breakthrough for the millions of people living with devastating neurodegenerative diseases.'.

“我们的研究结果已经表明，我们的融合蛋白结合了三种单克隆抗体的治疗优势，同时解决了脑部递送和安全性方面的许多关键局限性。最终，我们的目标是为数百万遭受毁灭性神经退行性疾病困扰的患者带来真正的突破。”

A uniquely positioned pan-amyloid immunotherapy platform

一个独特定位的泛淀粉样蛋白免疫治疗平台

Unlike current antibody therapies that each target a single pathological protein, Amyl Tx is developing a single therapy, a fusion protein designed to recognize and neutralize the common amyloid structure shared by multiple toxic (amyloid) protein aggregates, (amyloid beta, tau and alpha-synuclein), implicated in Alzheimer’s, Parkinson’s and related neurodegenerative diseases..

与目前每种仅针对单一病理蛋白的抗体疗法不同，Amyl Tx 正在开发一种单一的融合蛋白疗法，旨在识别并中和多种毒性淀粉样蛋白聚集体（包括β-淀粉样蛋白、tau蛋白和α-突触核蛋白）所共有的常见淀粉样结构，这些蛋白聚集体与阿尔茨海默病、帕金森病及相关神经退行性疾病密切相关。

Amyl Tx’s platform also incorporates a ‘brain shuttle’ technology that significantly enhances passage across the blood-brain barrier, overcoming an important limitation for existing biologics. In addition, Amyl Tx’s therapeutic design has been engineered to reduce the risk of potential side-effects, ARIA (Amyloid-Related Imaging Abnormalities), and anemia observed with current anti-amyloid-beta monoclonal antibodies, potentially offering a superior safety profile..

Amyl Tx 的平台还整合了“脑穿梭”技术，显著增强了跨越血脑屏障的能力，克服了现有生物制剂的一个重要局限。此外，Amyl Tx 的治疗设计经过工程化优化，旨在降低当前抗淀粉样蛋白-β单克隆抗体所见的潜在副作用风险，包括淀粉样蛋白相关影像学异常（ARIA）和贫血，从而可能提供更优越的安全性特征。

“We have continued to invest in Amyl Therapeutics because its platform has the potential to redefine how neurodegenerative diseases are treated. The team has consistently delivered on scientific milestones and this financing provides the resources to generate the critical data that will strengthen the company’s clinical path,” said Valérie Calenda, managing partner at Merieux Equity Partners..

“我们持续投资Amyl Therapeutics，因为其平台有望重新定义神经退行性疾病的治疗方式。该团队始终如一地实现了科学里程碑，而此次融资将提供生成关键数据所需的资源，从而强化公司的临床开发路径。”Merieux Equity Partners的管理合伙人Valérie Calenda表示。

Since its creation, Amyl Tx has built significant financial and scientific momentum, raising €10.8M at launch in March 2021, including €5.1M in-kind contribution for the acquisition of its IP and €2.2M in non-dilutive grants. The company obtained €5M in additional shareholder investment during 2023-2024 and €3.8M in non-dilutive support from the Walloon Region, Belgium.

自创立以来，Amyl Tx 在财务和科学方面积累了显著的势头，于2021年3月启动时筹集了1,080万欧元，其中包括为获取其知识产权而获得的510万欧元实物出资，以及220万欧元的非稀释性资助。在2023至2024年间，公司又获得了500万欧元的额外股东投资，以及来自比利时瓦隆大区的380万欧元非稀释性支持。

Today’s €8.25M brings its total funding to €27.85M..

今天的825万欧元融资使其总融资额达到2785万欧元。

“As a long-standing shareholder, Noshaq has witnessed Amyl Therapeutic’s steady scientific progress and the exceptional expertise and unwavering commitment of its  team. We are proud to continue supporting Amyl as it reaches the pivotal

“作为长期股东，Noshaq 见证了 Amyl Therapeutic 在科学上的稳步进展，以及其团队卓越的专业知识和坚定的承诺。我们自豪地继续支持 Amyl，助力其迈向关键的

in vivo

体内

milestones that will position the company for its next phase of growth,’ said Hélène Sabatel, investment manager at Noshaq.

“这些里程碑将为公司的下一轮增长奠定基础。”Noshaq 的投资经理埃莱娜·萨巴泰尔表示。

https://www.bionity.com/en/news/1189740/amyl-therapeutics-secures-8-25m-series-a-extension-to-validate-novel-neurodegenerative-disease-platform.html

https://www.bionity.com/en/news/1189740/amyl-therapeutics-secures-8-25m-series-a-extension-to-validate-novel-neurodegenerative-disease-platform.html

How CRISPR can help fight against neurodegenerative diseases

CRISPR如何助力对抗神经退行性疾病

Scientists listed ways of applying genetic engineering to treat Parkinson's disease

科学家列出了应用基因工程治疗帕金森病的方法

Read news

阅读新闻

Most read news

阅读最多的新闻

1

1

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI

诺和诺德与亚马逊云科技（AWS）建立战略合作伙伴关系，通过人工智能加速药物研发

2

2

Computomics raises EUR 6.3 million to scale climate-smart plant breeding

Computomics 融资 630 万欧元，以扩大气候智能型植物育种规模

3

3

The quantum computer microscope

量子计算机显微镜

4

4

Mould toxins in food are not destroyed during cooking or baking

食物中的霉菌毒素在烹饪或烘焙过程中不会被破坏

5

五

Scientists turn COVID-19 immune memory into a powerful new ally against cancer

科学家将新冠免疫记忆转化为对抗癌症的强大新盟友

Topics

主题

Series A financing

A轮融资

amyloid fibrils

淀粉样纤维

fusion proteins

融合蛋白

neurodegenerative diseases

神经退行性疾病

Parkinson's disease

帕金森病

dementia

痴呆症

Alzheimer's disease

阿尔茨海默病

Show all

显示全部

Show less

显示更少

Organizations

组织

Amyl Therapeutics

Amyl Therapeutics